Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron/Sanofi’s PSCK9 Inhibitor Might Need Two-Week Dosing Schedule

This article was originally published in The Pink Sheet Daily

Executive Summary

Fully human antibody for hypercholesterolemia is set to enter Phase III next month, and while the firms aren’t discussing the protocol, recent data suggest that REGN727/SRA236553 may need dosing every two weeks, rather than the more convenient monthly schedule.

You may also be interested in...



Aegerion Juxtapid Launch Targets Population Far Broader Than FDA Projection

Aegerion says feedback from key opinion leaders and market research indicate the market for its homozygous hypercholesterolemia drug may be as many as 3,000 patients; FDA estimates put the number at 315.

Amgen Keeping Dosing Options Open For Cholesterol Buster AMG 145

A monthly dose of Amgen’s PCSK9 inhibitor lowers LDL significantly with a good tolerability profile in two Phase II studies. Reporting results for the RUTHERFORD trial in the journal Circulation, investigators compare AMG 145 favorably for heterozygous familial hypercholesterolemia to a range of rivals, including Sanofi’s REGN 727, Genzyme’s mipomersen and Aegerion’s lomitapide.

PCSK9 In The Spotlight Ahead Of AHA Meeting

Publication of full Phase II results for Sanofi/Regeneron’s SRA236553 in the New England Journal of Medicine put the focus on the PCSK9 class days ahead of the annual AHA meeting, where Amgen and Pfizer will be presenting new data for rival drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel